Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke : A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial
© 2023. The Author(s)..
BACKGROUND: Ischemic stroke is a major cause of disability and death worldwide. A narrow therapeutic window profoundly constrained the utilization of alteplase.
OBJECTIVES: To investigate therapeutic effects and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke (AIS) in the 4.5-6 h therapeutic time windows.
METHODS: We conducted a phase IIa, randomized, and open-label multicenter clinical trial. Between 4.5 and 6 h after the onset of AIS, patients were randomly administrated to receive intravenous rhPro-UK at a 50 mg or 35 mg dose. The primary endpoint was excellent functional outcome defined as modified Rankin scale (mRS) score of 1 or less at 90 days. The secondary outcome was the treatment response, which was based on an at least 4-point improvement from baseline National Institutes of Health stroke scale (NIHSS) score at 24 h after drug administration. Safety endpoints included death, symptomatic intracerebral hemorrhage (sICH), and other serious adverse events.
RESULTS: We enrolled 80 patients in the 4.5-6 h therapeutic time windows at 17 medical centers in China from December 2016 to November 2017. A total of 39 patients were treated with 50 mg rhPro-UK, and 39 were treated with 35 mg rhPro-UK. Compared with the baseline, the NIHSS score at 24 h and days 7, 14, 30, and 90 was decreased significantly among patients treated with either rhPro-UK 50 mg or 35 mg. The mean reduction in the NIHSS from baseline to 90 days after the onset was 3.56 and 5.79 in the rhPro-UK 50 mg group and the rhPro-UK 35 mg group, respectively. The rates of functional independence at 90 days of rhPro-UK 50 mg and 35 mg were 61.54% and 69.23%, respectively (P = 0.475), and the proportion of patients with functional response to treatment at 24 h were 28.21% and 33.33% (P = 0.624). No sICH occurred in the two groups, and death occurred in only one patient in the rhPro-UK 50 mg group. There was no significant difference in mortality at 90 days and the rate of other serious adverse events between two groups.
CONCLUSION: In the 4.5-6 h time window, more than 60% of patients at either dose of rhPro-UK (50 mg or 35 mg) achieved functional independence at 90 days without increased mortality and sICH risk. Thus, intravenous rhPro-UK was effective and safe for patients with AIS within 4.5-6 h after stroke onset. While no significant differences were identified between different dosages of rhPro-UK regarding clinical outcomes, it is a logical step to further test the safety and efficacy of the low dose of rhPro-UK in a well-powered phase III study.
TRIAL REGISTRATION: http://www.chictr.org.cn . Identifier: ChiCTR1800016519. Date of registration: 6 June 2018.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
CNS drugs - 38(2024), 1 vom: 27. Jan., Seite 67-75 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Song, Haiqing [VerfasserIn] |
---|
Links: |
---|
Themen: |
Clinical Trial, Phase II |
---|
Anmerkungen: |
Date Completed 29.01.2024 Date Revised 19.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s40263-023-01051-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365220078 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM365220078 | ||
003 | DE-627 | ||
005 | 20240419232144.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40263-023-01051-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1380.xml |
035 | |a (DE-627)NLM365220078 | ||
035 | |a (NLM)38030867 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Song, Haiqing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke |b A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.01.2024 | ||
500 | |a Date Revised 19.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: Ischemic stroke is a major cause of disability and death worldwide. A narrow therapeutic window profoundly constrained the utilization of alteplase | ||
520 | |a OBJECTIVES: To investigate therapeutic effects and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke (AIS) in the 4.5-6 h therapeutic time windows | ||
520 | |a METHODS: We conducted a phase IIa, randomized, and open-label multicenter clinical trial. Between 4.5 and 6 h after the onset of AIS, patients were randomly administrated to receive intravenous rhPro-UK at a 50 mg or 35 mg dose. The primary endpoint was excellent functional outcome defined as modified Rankin scale (mRS) score of 1 or less at 90 days. The secondary outcome was the treatment response, which was based on an at least 4-point improvement from baseline National Institutes of Health stroke scale (NIHSS) score at 24 h after drug administration. Safety endpoints included death, symptomatic intracerebral hemorrhage (sICH), and other serious adverse events | ||
520 | |a RESULTS: We enrolled 80 patients in the 4.5-6 h therapeutic time windows at 17 medical centers in China from December 2016 to November 2017. A total of 39 patients were treated with 50 mg rhPro-UK, and 39 were treated with 35 mg rhPro-UK. Compared with the baseline, the NIHSS score at 24 h and days 7, 14, 30, and 90 was decreased significantly among patients treated with either rhPro-UK 50 mg or 35 mg. The mean reduction in the NIHSS from baseline to 90 days after the onset was 3.56 and 5.79 in the rhPro-UK 50 mg group and the rhPro-UK 35 mg group, respectively. The rates of functional independence at 90 days of rhPro-UK 50 mg and 35 mg were 61.54% and 69.23%, respectively (P = 0.475), and the proportion of patients with functional response to treatment at 24 h were 28.21% and 33.33% (P = 0.624). No sICH occurred in the two groups, and death occurred in only one patient in the rhPro-UK 50 mg group. There was no significant difference in mortality at 90 days and the rate of other serious adverse events between two groups | ||
520 | |a CONCLUSION: In the 4.5-6 h time window, more than 60% of patients at either dose of rhPro-UK (50 mg or 35 mg) achieved functional independence at 90 days without increased mortality and sICH risk. Thus, intravenous rhPro-UK was effective and safe for patients with AIS within 4.5-6 h after stroke onset. While no significant differences were identified between different dosages of rhPro-UK regarding clinical outcomes, it is a logical step to further test the safety and efficacy of the low dose of rhPro-UK in a well-powered phase III study | ||
520 | |a TRIAL REGISTRATION: http://www.chictr.org.cn . Identifier: ChiCTR1800016519. Date of registration: 6 June 2018 | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Fibrinolytic Agents |2 NLM | |
650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
650 | 7 | |a EC 3.4.21.68 |2 NLM | |
700 | 1 | |a Wang, Yuan |e verfasserin |4 aut | |
700 | 1 | |a Ma, Qingfeng |e verfasserin |4 aut | |
700 | 1 | |a Chen, Huisheng |e verfasserin |4 aut | |
700 | 1 | |a Liu, Bo |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yi |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Jianguo |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Shigang |e verfasserin |4 aut | |
700 | 1 | |a Jin, Xiaoping |e verfasserin |4 aut | |
700 | 1 | |a Li, Yongqiu |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yanyong |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Runxiu |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Liandong |e verfasserin |4 aut | |
700 | 1 | |a Liu, Junyan |e verfasserin |4 aut | |
700 | 1 | |a Feng, Wuwei |e verfasserin |4 aut | |
700 | 1 | |a Liu, Rui |e verfasserin |4 aut | |
700 | 1 | |a Ji, Xunming |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yuping |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t CNS drugs |d 1994 |g 38(2024), 1 vom: 27. Jan., Seite 67-75 |w (DE-627)NLM09374627X |x 1179-1934 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2024 |g number:1 |g day:27 |g month:01 |g pages:67-75 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40263-023-01051-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 38 |j 2024 |e 1 |b 27 |c 01 |h 67-75 |